GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 12.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 538,588 shares of the company's stock after buying an additional 58,465 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.14% of GoodRx worth $2,504,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Steward Partners Investment Advisory LLC acquired a new stake in shares of GoodRx during the 4th quarter worth $56,000. SBI Securities Co. Ltd. purchased a new stake in GoodRx during the fourth quarter valued at about $92,000. Verus Capital Partners LLC purchased a new stake in GoodRx during the fourth quarter valued at about $55,000. Versor Investments LP acquired a new stake in GoodRx during the fourth quarter worth about $54,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of GoodRx by 10.1% in the 4th quarter. Bank of New York Mellon Corp now owns 192,612 shares of the company's stock worth $896,000 after purchasing an additional 17,633 shares during the period. Institutional investors and hedge funds own 63.77% of the company's stock.

GoodRx Stock Up 3.2 %

Shares of GoodRx stock traded up $0.14 during trading hours on Wednesday, hitting $4.57. 1,470,460 shares of the company's stock traded hands, compared to its average volume of 1,366,614. GoodRx Holdings, Inc. has a twelve month low of $4.09 and a twelve month high of $9.26. The company has a market cap of $1.75 billion, a PE ratio of -152.33, a PEG ratio of 2.46 and a beta of 1.25. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a 50 day simple moving average of $4.75 and a 200-day simple moving average of $5.23.

Remove Ads

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Morgan Stanley decreased their target price on GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Wells Fargo & Company decreased their price objective on shares of GoodRx from $9.00 to $8.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Mizuho started coverage on shares of GoodRx in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 target price on the stock. Citigroup decreased their price target on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a research report on Friday, January 10th. Finally, KeyCorp cut their price objective on GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $8.18.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.